ACKC is a grassroots organization established in 2003 by kidney cancer patients and their families/caregivers who are working to raise awareness of kidney cancer and to ensure that it receives the public and private funding required to identify and develop effective treatment modalities and to find a cure for this disease. More >

Blog

  • A look at IL-15 and IL-2

    April 25th, 2012 Chris Battle, survivor

    IL-15 is a cousin of IL-2, but it is believed to be more targeted than the latter. Both drugs are immunotherapeutic,attempting to kickstart the body’s natural immune system into fighting the cancer naturally. Each tries to increase and activate lymphocyites which house Natural Kill Cells. I’m not making this up; Natural Killer Cellsis actually what they are called. And although they sound like murderous psychotics, and to some degree they are, they are on our side. Like the body’s own mob hit men.

  • IL-15: A new immunotherapy trial for kidney cancer patients

    April 18th, 2012 Chris Battle, survivor

    Kidney cancer patient Chris Battle shares his experiences as he undergoes a new Phase I trial with the drug IL-15.

  • Why ACKC is More Important Than Ever

    April 10th, 2012 Staff

    Take a few minutes to read this article from the Cancer Network website: http://www.cancernetwork.com/conference-reports/aacr2012/content/article/10165/2055542 This is why ACKC is working so hard on our lobbying efforts this year – to be sure that millions of dollars of funding available for kidney cancer research doesn’t get eliminated from the federal budget. PLEASE contact your US Senators [...]

See All

News

  • Dr. Janice Dutcher Moves Offices Dr. Janice Dutcher has moved her clinical practice and IL-2 treatment program from the Montefiore Medical Center in the Bronx to the St. Luke’s Roosevelt Hospital Center in Manhattan where Dr. Dutcher is the Director of the Immunotherapy Program. More >

  • Stanford University Researchers Identify Kidney Cancer Killer Stanford University researchers have discovered a molecule that directly attacks kidney cancer cells that have the VHL tumor-suppressor gene mutated or disabled. VHL deficient genes are present in 85-90% of clear cell carcinoma, the most prevalent type of kidney cancer. More >

Events